Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
$4.75
$5.40
$1.01
$7.42
$80.61M2.2264,087 shs67,714 shs
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$6.86
+2.1%
$4.99
$1.86
$9.01
$17.77M1.0367,576 shs26,465 shs
Praxsyn Co. stock logo
PXYN
Praxsyn
$0.00
$0.00
$0.01
$85K-1.01N/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
$3.85
$3.51
$2.50
$4.42
$6.72M-0.123,200 shsN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$0.16
$0.15
$0.12
$1.52
$2.48M1.281.66 million shs150,407 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
0.00%-11.21%-23.39%+3.04%+227.63%
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
+2.08%+43.51%+38.59%+140.70%+93.63%
Praxsyn Co. stock logo
PXYN
Praxsyn
0.00%0.00%0.00%0.00%0.00%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%+5.77%-3.75%+4.05%+5.48%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+1.02%-4.22%+12.77%-4.45%-84.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
2.0721 of 5 stars
3.53.00.00.02.91.70.0
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
1.5552 of 5 stars
3.53.00.00.02.30.80.0
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
2.2496 of 5 stars
3.55.00.00.00.60.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
3.00
Buy$19.00300.00% Upside
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
3.00
Buy$16.00133.24% Upside
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.00
Buy$3.251,944.03% Upside

Current Analyst Ratings

Latest RELV, ALRN, BNTC, PXYN, and SNOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
4/18/2024
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $19.00
2/15/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
1/24/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$80K222.09N/AN/A$0.12 per share57.17
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.19$0.09 per share44.53$6.36 per share0.61
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.27M0.19N/AN/A$1.72 per share0.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$19.56MN/A0.00N/AN/A-204.34%-142.81%5/20/2024 (Estimated)
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$5.15M-$0.97N/AN/AN/A-41.24%-58.93%-26.92%6/19/2024 (Estimated)

Latest RELV, ALRN, BNTC, PXYN, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/13/2024Q2 2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/A-$2.64-$2.64-$2.64N/AN/A
2/8/202412/31/2023
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.21-$0.06+$0.15-$0.04N/A$3.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/A
4.17
4.17
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
0.01
3.62
3.62
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
4.07
3.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
90.89%
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
52.19%
Praxsyn Co. stock logo
PXYN
Praxsyn
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
616.97 million16.03 millionNot Optionable
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
182.59 million2.48 millionNo Data
Praxsyn Co. stock logo
PXYN
Praxsyn
66847.94 millionN/ANot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
915.61 million14.17 millionNot Optionable

RELV, ALRN, BNTC, PXYN, and SNOA Headlines

SourceHeadline
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
finanznachrichten.de - April 9 at 10:39 AM
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
accesswire.com - April 9 at 7:30 AM
Sonoma Pharmaceuticals Reports Recent Publication…Sonoma Pharmaceuticals Reports Recent Publication…
pharmiweb.com - April 4 at 10:28 AM
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract InfectionsSonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
accesswire.com - April 4 at 7:30 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
finanznachrichten.de - March 28 at 9:52 PM
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
accesswire.com - March 28 at 4:01 PM
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other TopicalsSonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
accesswire.com - March 27 at 7:30 AM
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - February 10 at 2:56 PM
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
finance.yahoo.com - February 8 at 4:32 PM
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily UseSonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
finance.yahoo.com - January 23 at 9:51 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finanznachrichten.de - November 13 at 5:52 PM
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finance.yahoo.com - November 13 at 5:52 PM
Sonoma Pharmaceuticals Inc SNOASonoma Pharmaceuticals Inc SNOA
morningstar.com - November 11 at 10:31 PM
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceSonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
finance.yahoo.com - November 3 at 8:49 AM
US Stocks Mixed; Bristol Myers Posts Upbeat EarningsUS Stocks Mixed; Bristol Myers Posts Upbeat Earnings
benzinga.com - October 26 at 6:54 PM
Crude Oil Down 2.5%; Mastercard Posts Upbeat EarningsCrude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
markets.businessinsider.com - October 26 at 6:54 PM
Dow Dips Over 100 Points; US GDP Growth Tops ExpectationsDow Dips Over 100 Points; US GDP Growth Tops Expectations
benzinga.com - October 26 at 1:54 PM
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common StockSonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 1:54 PM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 10:20 PM
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 5:19 PM
macOS Sonoma now available: Heres whats newmacOS Sonoma now available: Here's what's new
pocketnow.com - September 29 at 3:54 PM
macOS SonomamacOS Sonoma
macrumors.com - September 28 at 12:39 PM
Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?
stuff.tv - September 14 at 7:13 AM
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedNational Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
finance.yahoo.com - August 15 at 10:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aileron Therapeutics logo

Aileron Therapeutics

NASDAQ:ALRN
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Benitec Biopharma logo

Benitec Biopharma

NASDAQ:BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Praxsyn logo

Praxsyn

OTCMKTS:PXYN
Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.
Reliv

Reliv' International

NASDAQ:RELV
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

NASDAQ:SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.